Differentiated Thyroid Cancer
International Survey
Differentiated Thyroid Cancer (DTC) is a rare and complex condition that presents a number of challenges for the patient and their family. In order to help the patient community in the best possible way, TCA and TFI, with the support of the pharmaceutical company Ipsen, would like to understand the DTC patients’ situation better.
Share your experiences with us and take part in our international survey if the following criteria apply to you:
- You are at least 18 years and not older than 75 years
- You have received the diagnosis “Differentiated Thyroid Cancer (DTC)”
- You received both a 1st line and a 2nd line systemic treatment after radioactive iodine therapy, i.e. your tumor returned a first time and you were treated (1st line treatment) and your tumor returned for a second time and you were treated (2nd line treatment)
- You had your 2nd line treatment reimbursed by your health insurance
- You have not been diagnosed with any other type of cancer besides DTC
By taking part, you support the work of your global patient organisation. This is because for every participant who answers the survey, the global patient organisation receives a contribution to help patients and their families. Moreover, we plan to publish the anonymized and aggregated results in a scientific journal to support the DTC patient community. We also would be pleased to share the results of the survey with you. It will take 25 minutes only to complete an online questionnaire and your data will of course be treated confidentially and evaluated anonymously.
The survey is scheduled for winter 2023/2024 and you’ll be sent an invitation link to the online survey. Would you like to take part? We are looking forward to hearing from you. Please contact Ms. Kathrin König from PARTNERSEITZ: hello@partnerseitz.d
More information: 3. For Patient Organisation_information sheet_Survey DTC_CANADA_EN_20240206
